Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Renal Anemia - Pipeline Insight, 2018 -

Research and Markets
Posted on: 20 Feb 18

The "Renal Anemia - Pipeline Insight, 2018" drug pipelines has been added to's offering.

'Renal Anemia - Pipeline Insight, 2018' report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Renal Anemia development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Renal Anemia

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Renal Anemia

The report assesses the active Renal Anemia pipeline products by developmental stage, product type, molecule type, and administration route.

Key Topics Covered:

1. Report Introduction

2. Renal Anemia Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Renal Anemia

4. Comparative Analysis

5. Products in Clinical Stage

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

Companies Mentioned

  • 3SBio Inc
  • Akebia Therapeutics Inc
  • Amgen Inc
  • Bayer AG
  • Betta Pharmaceuticals Co Ltd
  • Biocad
  • CCM Duopharma Biotech Bhd
  • Chong Kun Dang Pharmaceutical Corp
  • CJ HealthCare Corp
  • Dong-A Socio Holdings Co Ltd
  • FibroGen Inc
  • GlaxoSmithKline Plc
  • Intas Pharmaceuticals Ltd
  • Japan Tobacco Inc
  • Novartis AG
  • Panacea Biotec Ltd

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 20/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.